Want to see TSE:PCLO full AI Analyst Report?
Top Page
PharmaCielo
(PCLO)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.06
▼(-5.00% Downside)
Action:Reiterated
Date:08/30/26
The score is primarily held down by weak financial performance—ongoing large losses, negative equity, and materially negative operating/free cash flow—despite improving revenue and gross margin. Technical indicators add modest pressure (below key moving averages and negative MACD), while valuation remains constrained by a negative P/E and no indicated dividend yield.
Positive Factors
Revenue rebound
The strong TTM revenue rebound indicates improving product demand or commercial reach. Sustained growth could provide operating leverage over time, although the company must convert higher sales into durable profitability.
Negative Factors
Persistent unprofitability
Despite revenue and margin improvement, the business remains far from covering operating costs. Persistent losses weaken internal funding capacity and mean future growth may require additional capital before scale benefits can emerge.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound
The strong TTM revenue rebound indicates improving product demand or commercial reach. Sustained growth could provide operating leverage over time, although the company must convert higher sales into durable profitability.
Read all positive factors
PharmaCielo (PCLO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$10.28M
Dividend YieldN/A
Average Volume (3M)56.12K
Price to Earnings (P/E)―
Beta (1Y)-3.83
Revenue Growth0.90%
EPS Growth57.73%
CountryCA
Employees268
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding221,005,070
10 Day Avg. Volume36,721
30 Day Avg. Volume56,116
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PharmaCielo Business Overview & Revenue Model
Company Description
PharmaCielo Ltd., operating in conjunction with its subsidiary, is primarily engaged in the comprehensive cultivation, processing, and distribution of pharmaceutical-grade cannabis extracts, including tetrahydrocannabinol (THC), and associated med...
How the Company Makes Money
PharmaCielo’s primary revenue model is business-to-business (B2B) sales of cannabis-derived ingredients and related products. The company seeks to monetize its operations by (1) cultivating and/or sourcing cannabis biomass and converting it into p...
PharmaCielo Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
18
Very Negative
Cash Flow
16
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Jun 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.60M | 2.61M | 3.48M | 1.54M | 5.31M | 1.94M |
| Gross Profit | 1.34M | 756.40K | 730.88K | -1.37M | 827.06K | -4.31M |
| EBITDA | -317.50K | -1.00M | -4.60M | -12.19M | -10.50M | -24.84M |
| Net Income | -3.71M | -4.55M | -9.14M | -16.30M | -16.04M | -26.92M |
Balance Sheet | ||||||
| Total Assets | 12.75M | 8.56M | 18.39M | 22.29M | 25.12M | 35.96M |
| Cash, Cash Equivalents and Short-Term Investments | 77.50K | 289.24K | 147.94K | 62.18K | 325.98K | 5.63M |
| Total Debt | 18.21M | 18.65M | 20.52M | 18.31M | 12.59M | 8.43M |
| Total Liabilities | 23.44M | 23.92M | 25.91M | 23.97M | 18.72M | 16.63M |
| Stockholders Equity | -10.70M | -15.35M | -7.52M | -1.68M | 6.39M | 19.33M |
Cash Flow | ||||||
| Free Cash Flow | -6.96M | -1.02M | -1.97M | -5.17M | -10.23M | -21.21M |
| Operating Cash Flow | -6.96M | -1.02M | -1.97M | -5.15M | -9.71M | -20.07M |
| Investing Cash Flow | 10.05M | 6.66M | 41.14K | 391.64K | -725.49K | -1.66M |
| Financing Cash Flow | -3.04M | -5.52M | 2.02M | 4.63M | 5.30M | 18.21M |
PharmaCielo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | C$32.04M | -6.47 | -13.79% | ― | -6.74% | 43.54% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$5.96M | -3.07 | -43.92% | ― | -18.30% | -397.37% | |
44 Neutral | C$9.00M | -6.95 | -19.37% | ― | -19.20% | 42.54% | |
42 Neutral | C$51.29M | -0.76 | -2099.75% | ― | -100.00% | 94.43% | |
41 Neutral | C$10.28M | -3.21 | 28.59% | ― | 0.90% | 57.73% | |
41 Neutral | C$15.45M | -3.40 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
TSE:PCLO
PharmaCielo
0.06
0.02
33.33%
TSE:ATLE
Willow Biosciences Inc
0.10
-0.06
-37.50%
TSE:LABS
MediPharm Labs
0.08
0.00
0.00%
TSE:OILS
Nextleaf Solutions
0.04
-0.04
-53.33%
TSE:AVCN
Avicanna
0.11
-0.16
-59.26%
TSE:INNO
InnoCan Pharma
2.00
-10.00
-83.33%
PharmaCielo Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
PharmaCielo Revenue Surges on European Cannabis Sales as It Preserves Cash with Share-Based Interest Payment
Positive
Aug 28, 2026
PharmaCielo reported a sharp rebound in its 2026 first quarter, with revenue rising to $1.4 million from $0.3 million a year earlier, driven by a broader geographic footprint and new dried flower sales into Europe. The company swung to a gross pro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.